JP2025016684A5 - - Google Patents
Info
- Publication number
- JP2025016684A5 JP2025016684A5 JP2024193094A JP2024193094A JP2025016684A5 JP 2025016684 A5 JP2025016684 A5 JP 2025016684A5 JP 2024193094 A JP2024193094 A JP 2024193094A JP 2024193094 A JP2024193094 A JP 2024193094A JP 2025016684 A5 JP2025016684 A5 JP 2025016684A5
- Authority
- JP
- Japan
- Prior art keywords
- thiadiazol
- difluoromethyl
- indazol
- amino
- sulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962903438P | 2019-09-20 | 2019-09-20 | |
| US62/903,438 | 2019-09-20 | ||
| PCT/US2020/051486 WO2021055744A1 (en) | 2019-09-20 | 2020-09-18 | 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors |
| JP2022517374A JP2022548690A (ja) | 2019-09-20 | 2020-09-18 | Ｐａｒｇ阻害剤としての４－置換インドールおよびインダゾールスルホンアミド誘導体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022517374A Division JP2022548690A (ja) | 2019-09-20 | 2020-09-18 | Ｐａｒｇ阻害剤としての４－置換インドールおよびインダゾールスルホンアミド誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025016684A JP2025016684A (ja) | 2025-02-04 |
| JP2025016684A5 true JP2025016684A5 (enExample) | 2025-09-08 |
| JP7781244B2 JP7781244B2 (ja) | 2025-12-05 |
Family
ID=72744866
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022517374A Ceased JP2022548690A (ja) | 2019-09-20 | 2020-09-18 | Ｐａｒｇ阻害剤としての４－置換インドールおよびインダゾールスルホンアミド誘導体 |
| JP2024193094A Active JP7781244B2 (ja) | 2019-09-20 | 2024-11-01 | Ｐａｒｇ阻害剤としての４－置換インドールおよびインダゾールスルホンアミド誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022517374A Ceased JP2022548690A (ja) | 2019-09-20 | 2020-09-18 | Ｐａｒｇ阻害剤としての４－置換インドールおよびインダゾールスルホンアミド誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220389003A1 (enExample) |
| EP (1) | EP4031249B1 (enExample) |
| JP (2) | JP2022548690A (enExample) |
| KR (1) | KR20220066922A (enExample) |
| CN (1) | CN114555593A (enExample) |
| AU (1) | AU2020348489B2 (enExample) |
| BR (1) | BR112022004624A2 (enExample) |
| CA (1) | CA3147493A1 (enExample) |
| DK (1) | DK4031249T3 (enExample) |
| FI (1) | FI4031249T3 (enExample) |
| IL (1) | IL291436B1 (enExample) |
| LT (1) | LT4031249T (enExample) |
| MX (1) | MX2022003276A (enExample) |
| PT (1) | PT4031249T (enExample) |
| TW (1) | TWI873187B (enExample) |
| WO (1) | WO2021055744A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| US20250002491A1 (en) | 2021-10-04 | 2025-01-02 | Forx Therapeutics Ag | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
| CA3225500A1 (en) | 2021-10-04 | 2023-04-13 | Ulrich Luecking | Parg inhibitory compounds |
| IL311851A (en) * | 2021-10-04 | 2024-05-01 | Forx Therapeutics Ag | PARG inhibitory compounds |
| CA3251360A1 (en) | 2022-02-14 | 2023-08-17 | Arase Therapeutics Inc. | PARG INHIBITORS |
| EP4488275A4 (en) * | 2022-03-04 | 2025-07-23 | Shanghai Yingli Pharm Co Ltd | COMPOUND CONTAINING A FIVE-MEMBERED HETEROAROMATIC RING STRUCTURE, PHARMACEUTICAL COMPOSITION AND USE THEREOF |
| WO2023175184A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| WO2023175185A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| PL4496795T3 (pl) * | 2022-03-23 | 2026-07-20 | Ideaya Biosciences, Inc. | Związki indazolowe podstawione piperazyną jako inhibitory parg |
| IL316261A (en) | 2022-04-28 | 2024-12-01 | Danatlas Pharmaceuticals Co Ltd | Tricyclic and heterocyclic derivatives, preparations and uses thereof |
| TW202409036A (zh) | 2022-05-17 | 2024-03-01 | 美商858療法股份有限公司 | Parg抑制劑 |
| TWI878939B (zh) * | 2022-06-29 | 2025-04-01 | 大陸商杭州聖域生物醫藥科技有限公司 | 五元並六元含氮化物、其中間體、製備方法和應用 |
| AU2023310489A1 (en) * | 2022-07-19 | 2025-02-13 | Evopoint Biosciences Co., Ltd. | Sulfur-containing heteroaromatic ring compound, pharmaceutical composition thereof, and use thereof |
| EP4311829A1 (en) | 2022-07-28 | 2024-01-31 | Nodus Oncology Limited | Substituted bicyclic heteroaryl sulfonamide derivatives for the treatment of cancer |
| IL320031A (en) | 2022-10-03 | 2025-06-01 | Forx Therapeutics Ag | Parg inhibitory compound |
| CN120051465A (zh) * | 2022-10-13 | 2025-05-27 | 韩美药品株式会社 | 用于抑制yap-tead交互作用的新颖杂双环化合物及包含其的药学组成物 |
| EP4646208A1 (en) | 2023-01-06 | 2025-11-12 | Ideaya Biosciences, Inc. | Treatment of er+ breast cancer comprising homologous recombination deficiency using parg inhibitor |
| WO2024173234A1 (en) * | 2023-02-13 | 2024-08-22 | Arase Therapeutics Inc. | Inhibitors of parg |
| WO2024173530A1 (en) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted pyrazolo/imidazo pyridine compounds |
| WO2024173524A1 (en) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted benzimidazole compounds |
| WO2024173453A1 (en) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted imidazopyridine compounds |
| WO2024173514A1 (en) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Amide and ester-substituted imidazopyridine compounds |
| WO2024209035A1 (en) | 2023-04-05 | 2024-10-10 | Forx Therapeutics Ag | Parg inhibitory compounds |
| AU2024253809A1 (en) | 2023-04-05 | 2025-10-16 | Ideaya Biosciences, Inc. | Combination therapy comprising a parg inhibitor and a topoisomerase inhibitor for treating cancer |
| CN121002021A (zh) * | 2023-04-27 | 2025-11-21 | 北京丹擎医药科技有限公司 | 三环杂环衍生物及其组合物和应用 |
| WO2024254990A1 (zh) | 2023-06-16 | 2024-12-19 | 上海璎黎药业有限公司 | 一种杂芳环结构化合物、其药物组合物及应用 |
| WO2025046148A1 (en) | 2023-09-01 | 2025-03-06 | Forx Therapeutics Ag | Novel parg inhibitors |
| WO2025064750A1 (en) | 2023-09-20 | 2025-03-27 | Ideaya Biosciences, Inc. | Combination therapy with a parg inhibitor |
| TW202528308A (zh) * | 2023-09-20 | 2025-07-16 | 美商愛德亞生物科學公司 | Parg抑制劑 |
| WO2025072544A1 (en) * | 2023-09-27 | 2025-04-03 | Ideaya Biosciences, Inc. | Sulfonamino indazole compounds as inhibitors of parg |
| WO2025067464A1 (zh) * | 2023-09-28 | 2025-04-03 | 杭州圣域生物医药科技有限公司 | 杂芳基化合物、其中间体、制备方法和应用 |
| KR20260084620A (ko) | 2023-10-03 | 2026-06-05 | 포알엑스 테라퓨틱스 아게 | Parg 억제 화합물 |
| WO2025082231A1 (zh) * | 2023-10-20 | 2025-04-24 | 上海璎黎药业有限公司 | 一种杂芳环磺酰胺结构化合物、其药物组合物及应用 |
| WO2025087941A1 (en) | 2023-10-23 | 2025-05-01 | Universite De Geneve | Parg inhibitors in combination with parp inhibitors and uses thereof |
| CN122249439A (zh) | 2023-10-26 | 2026-06-19 | 上海齐鲁制药研究中心有限公司 | Parg抑制剂 |
| WO2025087274A1 (zh) | 2023-10-27 | 2025-05-01 | 浙江海正药业股份有限公司 | 氮杂双环类衍生物及其制备方法和用途 |
| WO2025093755A1 (en) | 2023-11-01 | 2025-05-08 | Forx Therapeutics Ag | Novel parc inhibitors |
| WO2025098445A1 (zh) * | 2023-11-07 | 2025-05-15 | 南京同诺康医药科技有限公司 | Parg抑制剂及其制备方法和用途 |
| WO2025108225A1 (zh) * | 2023-11-20 | 2025-05-30 | 上海复星医药（集团）股份有限公司 | 作为parg抑制剂的含氮三环衍生物 |
| WO2025111339A1 (en) * | 2023-11-21 | 2025-05-30 | 858 Therapeutics, Inc. | Treatment of cancer with a parg inhibitor |
| AR134429A1 (es) * | 2023-11-22 | 2026-01-14 | 858 Therapeutics Inc | Inhibidores de parg |
| WO2025133396A1 (en) | 2023-12-22 | 2025-06-26 | Forx Therapeutics Ag | Novel bicyclo heteroaryl parg inhibitors |
| WO2025133191A1 (en) * | 2023-12-22 | 2025-06-26 | Genecode | Novel sulfonamides or sulfones and their use as neuroprotective and/or neurorestorative agents |
| WO2025229549A1 (en) * | 2024-04-30 | 2025-11-06 | Satyarx Pharma Innovations Pvt Ltd | Novel heterocyclic compounds as inhibitors of parg |
| CN118459452B (zh) * | 2024-07-10 | 2024-10-25 | 苏州国匡医药科技有限公司 | 一种多聚adp核糖水解酶抑制剂及其应用 |
| WO2026022150A1 (en) | 2024-07-22 | 2026-01-29 | Forx Therapeutics Ag | Parg inhibitory compounds |
| TW202610628A (zh) * | 2024-07-29 | 2026-03-16 | 大陸商海思科醫藥集團股份有限公司 | 磺醯胺化合物及其在醫藥上的應用 |
| WO2026032385A1 (zh) * | 2024-08-07 | 2026-02-12 | 上海亚虹医药科技有限公司 | 多聚adp核糖水解酶抑制剂及其医药用途 |
| WO2026040953A1 (zh) * | 2024-08-19 | 2026-02-26 | 上海和誉生物医药科技有限公司 | 一种多环parg抑制剂和其应用 |
| WO2026042050A1 (en) * | 2024-08-23 | 2026-02-26 | Recursion Pharmaceuticals, Inc. | Novel compounds and uses thereof |
| WO2026060261A1 (en) * | 2024-09-13 | 2026-03-19 | Equator Therapeutics, Inc. | Compositions and methods for treating metabolic disorders |
| WO2026062066A1 (en) | 2024-09-17 | 2026-03-26 | Forx Therapeutics Ag | Compounds inducing parg degradation |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| EE05345B1 (et) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| KR20030014425A (ko) | 2000-07-07 | 2003-02-17 | 앤지오젠 파마슈티칼스 리미티드 | 혈관 손상제인 콜치놀 유도체 |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| CA2834101A1 (en) * | 2011-01-07 | 2012-07-12 | Taiho Pharmaceutical Co., Ltd. | Novel indole or indazole derivative or salt thereof |
| MA41140A (fr) * | 2014-12-12 | 2017-10-17 | Cancer Research Tech Ltd | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |
| MA41179A (fr) * | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| AU2018352695A1 (en) * | 2017-10-19 | 2020-05-28 | Effector Therapeutics, Inc. | Benzimidazole-indole inhibitors of Mnk1 and Mnk2 |
| PT3870575T (pt) * | 2018-10-25 | 2023-05-12 | Viiv Healthcare Uk No 5 Ltd | Inibidores da replicação do vírus da imunodeficiência humana |
| PL4496795T3 (pl) * | 2022-03-23 | 2026-07-20 | Ideaya Biosciences, Inc. | Związki indazolowe podstawione piperazyną jako inhibitory parg |
-
2020
- 2020-09-17 IL IL291436A patent/IL291436B1/en unknown
- 2020-09-18 TW TW109132483A patent/TWI873187B/zh active
- 2020-09-18 MX MX2022003276A patent/MX2022003276A/es unknown
- 2020-09-18 FI FIEP20786137.8T patent/FI4031249T3/fi active
- 2020-09-18 US US17/761,935 patent/US20220389003A1/en active Pending
- 2020-09-18 KR KR1020227012903A patent/KR20220066922A/ko active Pending
- 2020-09-18 EP EP20786137.8A patent/EP4031249B1/en active Active
- 2020-09-18 DK DK20786137.8T patent/DK4031249T3/da active
- 2020-09-18 CN CN202080065861.1A patent/CN114555593A/zh active Pending
- 2020-09-18 WO PCT/US2020/051486 patent/WO2021055744A1/en not_active Ceased
- 2020-09-18 BR BR112022004624A patent/BR112022004624A2/pt unknown
- 2020-09-18 PT PT207861378T patent/PT4031249T/pt unknown
- 2020-09-18 LT LTEPPCT/US2020/051486T patent/LT4031249T/lt unknown
- 2020-09-18 AU AU2020348489A patent/AU2020348489B2/en active Active
- 2020-09-18 JP JP2022517374A patent/JP2022548690A/ja not_active Ceased
- 2020-09-18 CA CA3147493A patent/CA3147493A1/en active Pending
-
2024
- 2024-11-01 JP JP2024193094A patent/JP7781244B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022548690A5 (enExample) | ||
| KR101985050B1 (ko) | 피라진카르복사미드 화합물 | |
| US8895733B2 (en) | Triazine-oxadiazoles | |
| KR101949624B1 (ko) | Tank-결합 키나제 억제제 화합물로서 유용한 아미노트리아진 유도체 | |
| IL295799A (en) | Trophomyosin receptor kinase (trk) degradation compounds and methods of use | |
| WO2022228547A1 (zh) | 一种膦酰衍生物及其组合物和药学上的应用 | |
| JP7651590B2 (ja) | アミノピリミジン誘導体およびアリール炭化水素受容体モジュレーターとしてのその使用 | |
| JP2025540958A (ja) | 蕁麻疹の治療のための野生型ｃ－ｋｉｔキナーゼ阻害剤としてのＮ－フェニル－ピラゾロ［１，５－Ａ］ピリジン－３－カルボキサミド誘導体 | |
| US20070249597A1 (en) | Pyrazoloquinolones are potent parp inhibitors | |
| JP2018522929A5 (enExample) | ||
| RU2015144485A (ru) | Геминально-замещенные цианоэтилпиразолопиридоны в качестве ингибиторов janus киназ | |
| JP2024009891A (ja) | Ｔ型カルシウムチャネル阻害剤 | |
| US9226916B2 (en) | Pyrrolidine derivatives | |
| US20240383875A1 (en) | Benzimidazole Pyridine Derivatives | |
| JP2022081710A (ja) | 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用 | |
| EP3950059A1 (en) | Use of t-type calcium channel blocker for treating pruritus | |
| JPWO2020203609A5 (enExample) | ||
| RU2010120536A (ru) | Производные пиридина и пиразина, полезные для лечения клеточных проферативных расстройств | |
| RU2826628C1 (ru) | Производные аминопиримидина и их применение в качестве модуляторов рецептора ароматических углеводородов | |
| KR20250087568A (ko) | Shp2 단백질 분해용 화합물 및 이들의 의약 용도 | |
| HK40086197A (en) | Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators |